HONG KONG, Nov. 18, 2023 /PRNewswire/ — Aligning with Toshiba TV’s commitment to crafting enduring models featuring dynamic sound and picture performance, the Z870 model stands out as a significant addition to its legacy. Continue Reading The recently concluded #MakingSoundVisible campaign surpassed the portrayal of the Z870 as a mere home entertainment centerpiece. With the… Continue reading Sonic Brilliance: Navigating the Legacy of #MakingSoundVisible with Toshiba TV
Category: Newswire
“CELEBRATION OF RESCUE” EVENT SPOTLIGHTS 360-DEGREE VIEW OF NORTH SHORE ANIMAL LEAGUE AMERICA’S LIFE-SAVING MISSION
Attendees Included Event Chairperson Beth Stern, Event Host Brian Balthazar, Event Entertainer Thelma Houston, Maya Hawke, Kathryn Erbe, Selenis Levya, Robyn Schall, Maria Milito, Dan Mannarino, Rocco DiSpirito, Will Ganss, and Others. Proceeds from Star-Studded Celebration Will Help Continue Animal League America’s No-Kill Mission to Rescue, Nurture, Adopt, And Educate NEW YORK, Nov. 17, 2023… Continue reading “CELEBRATION OF RESCUE” EVENT SPOTLIGHTS 360-DEGREE VIEW OF NORTH SHORE ANIMAL LEAGUE AMERICA’S LIFE-SAVING MISSION
HOLLEY SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Holley To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Holley between July 21, 2021 and February 6, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/HLLY. There is no cost or obligation to you. NEW… Continue reading HOLLEY SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Holley To Contact Him Directly To Discuss Their Options
PURECYCLE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PureCycle To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in PureCycle stock or options between August 8, 2023 and September 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/PCT. There is no cost or obligation… Continue reading PURECYCLE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PureCycle To Contact Him Directly To Discuss Their Options
DLOCAL SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In DLocal To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in DLocal stock or options between May 2, 2022 and May 25, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DLO. There is no cost or obligation… Continue reading DLOCAL SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In DLocal To Contact Him Directly To Discuss Their Options
‘Learning Mandarin in Taiwan!’ Taiwan becomes the top destination for studying Mandarin
TAIPEI, Nov. 17, 2023 /PRNewswire/ — Taiwan has become a top destination for American students to learn and study Mandarin. Taiwan’s free society, welcoming people, convenient environment, exceptional scenery, and robust healthcare system are among the many reasons why foreigners choose to study, work, or live in Taiwan. ACTFL Convention and World Languages Expo Continue… Continue reading ‘Learning Mandarin in Taiwan!’ Taiwan becomes the top destination for studying Mandarin
Global Stem Cell Collaboration and Licensing Agreements Analysis Report 2023 with Directory of 150+ Deals Signed Since 2016
DUBLIN, Nov. 17, 2023 /PRNewswire/ — The “Stem Cell Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering. This report contains a comprehensive listing of 158 stem cell deals announced since 2016 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal… Continue reading Global Stem Cell Collaboration and Licensing Agreements Analysis Report 2023 with Directory of 150+ Deals Signed Since 2016
Global Immunology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed by the World’s Leading Biopharma Companies Since 2016
DUBLIN, Nov. 17, 2023 /PRNewswire/ — The “Immunology Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering. Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of immunology deals from… Continue reading Global Immunology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed by the World’s Leading Biopharma Companies Since 2016
Global Genitourinary Collaboration and Licensing Agreement Analysis Report 2023 with Directory of Deals Signed by the World’s Leading Biopharma Companies Since 2016
DUBLIN, Nov. 17, 2023 /PRNewswire/ — The “Genitourinary Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering. Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of genitourinary deals from… Continue reading Global Genitourinary Collaboration and Licensing Agreement Analysis Report 2023 with Directory of Deals Signed by the World’s Leading Biopharma Companies Since 2016
Global Metabolic Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed Since 2016
DUBLIN, Nov. 17, 2023 /PRNewswire/ — The “Metabolic Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering. Metabolic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the metabolic deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of metabolic deals from… Continue reading Global Metabolic Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed Since 2016